Exenatide treatment improves adiponectin and CRP levels
MedWire News: Treatment with the oral hypoglycemic drug exenatide has beneficial effects on adiponectin and C-reactive protein (CRP) levels, suggest study findings published in the journal Diabetes Care.
These findings provide further evidence for the benefits of treatment with exenatide, adding to previous results demonstrating its potential for reducing body weight and improving glycemic control.
Mathijs Bunck (VU University Medical Center, Amsterdam, The Netherlands) and colleagues carried out a study of 57 Type 2 diabetes patients who were inadequately controlled on metformin therapy to assess the effects of exenatide versus insulin glargine on body composition and circulating biomarkers.
The participants were randomly assigned to take exenatide (n=29) or insulin glargine (n=28) in addition to metformin for a period of 1 year.
Compared with those treated with insulin glargine, patients treated with exenatide had reductions in body weight, waist circumference, and total body and trunkal fat mass of 6%, 5%, 11%, and 13%, respectively, at 1 year.
In addition, exenatide-treated patients had a 12% increase and 61% decrease in adiponectin and CRP levels, respectively, at 1 year compared with insulin glargine-treated patients.
The researchers say these biochemical changes were only partly attributable to the observed reductions in body weight and fat mass, but concede that their study was small and that further research would be needed to confirm this result.
Of note, patients treated with insulin glargine had a significant 7% reduction in endothelin-1 at study completion compared with exenatide-treated patients. But no significant additional changes in body composition or circulating biomarkers were seen in this group.
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010
By Helen Albert